For the readers interested in the stock health of Artelo Biosciences Inc. (ARTL). It is currently valued at $1.44. When the transactions were called off in the previous session, Stock hit the highs of $1.57, after setting-off with the price of $1.35. Company’s stock value dipped to $1.32 during the trading on the day. When the trading was stopped its value was $1.28.
Recently in News on February 8, 2021, Artelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants. Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the exercise of a portion of the warrants from its October 2020 financing. Existing investors agreed to exercise warrants for net proceeds of approximately $3 million. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Artelo Biosciences Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.7300 on 02/02/21, with the lowest value was $0.7460 for the same time period, recorded on 01/04/21.
Artelo Biosciences Inc. (ARTL) full year performance was -15.79%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Artelo Biosciences Inc. shares are logging -30.10% during the 52-week period from high price, and 219.29% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.45 and $2.06.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 6778353 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Artelo Biosciences Inc. (ARTL) recorded performance in the market was 97.26%, having the revenues showcasing 156.59% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 23.80M, as it employees total of 3 workers.
The Analysts eye on Artelo Biosciences Inc. (ARTL)
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.7648, with a change in the price was noted +0.5420. In a similar fashion, Artelo Biosciences Inc. posted a movement of +60.36% for the period of last 100 days, recording 3,357,512 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ARTL is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Artelo Biosciences Inc. (ARTL)
Raw Stochastic average of Artelo Biosciences Inc. in the period of last 50 days is set at 75.67%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 65.88%. In the last 20 days, the company’s Stochastic %K was 49.41% and its Stochastic %D was recorded 44.44%.
Considering, the past performance of Artelo Biosciences Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 97.26%. Additionally, trading for the stock in the period of the last six months notably improved by 17.07%, alongside a downfall of -15.79% for the period of the last 12 months. The shares increased approximately by 15.20% in the 7-day charts and went down by 37.14% in the period of the last 30 days. Common stock shares were driven by 156.59% during last recorded quarter.